Diamed Obesity S.R.L. — Clinical Trial Site

15 Registered trials

3 Currently recruiting

Organisation

Diamed Obesity S.R.L.

Location

Galati, Romania

Identifier

ORG-100042805

Address

Gheorghe Doja Nr 73, 800291, Romania

Departments

Diabet
Diabetes
Diabetes and Metabolic diseases
Diabetes-Nutrition-Metabolic Disorders
Diabetes, metabolic diseases
Diabetes, Nutrition and Metabolic Diseases
Diabetes, Nutrition and Metabolic Diseases; Internal Medicine
Medicina Interna
N/A
NA
Private Practice, Diabetes and Cardiology
Societatea Diamed Obesity SRL
Specialitatea–Diabet zaharat, nutritie si boli metabolice

Clinical trials at this site (15)

Search interface

Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting

2024-519712-13-00 Hypertriglyceridemia (HTG) 5 2025-12-08
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination wi… Recruiting

2024-519945-31-00 Type 1 Diabetes 5 2025-08-21
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA 3 Study) Ended

2023-509300-14-00 Severe hypertriglyceridemia (SHTG) 5 2024-10-31
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended

2022-501744-15-00 Obesity, Overweight 5 2023-01-23
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended

2023-506926-35-00 Atherosclerotic cardiovascular disease, chronic kidney 5 2021-09-24
Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended

2023-506962-30-00 Non-alcoholic steatohepatitis (NASH) 5 2021-03-29
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or With… Ended

2023-507280-18-00 Type 2 Diabetes 5 2024-02-23
A Study of LY3437943 in Participants Who Have Obesity or Overweight (TRIUMPH-1) Ended

2023-503657-35-00 Obesity 5 2023-10-10
A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase… Ended

2022-502833-25-00 Obesity 5 2023-08-02
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV… Ended

2023-507846-96-00 Type 2 Diabetes Mellitus 5 2020-06-19